-
Uncategorized3 weeks ago
Novartis Buys Breast Cancer Drug for $2B to Keep Up With Myriad Rivals
Aside from the $2 billion upfront payment, Novartis is also putting up to $1 billion on the line in milestones for Synnovation Therapeutics’ pan-mutant-selective PI3Kα blocker.
-
Uncategorized3 weeks agoEvotec to receive $10m as kidney cancer trial launches
Evotec will receive a $10 million milestone payment as a kidney cancer trial has got underway. Bristol Myers Squibb has launched its Phase I clinical study evaluating CELMoD agent BMS-986506, a cereblon E3...
-
Uncategorized3 weeks ago
Roche Ends Run for Muscular Atrophy Drug, Leaving Door Open for Competitors
The main beneficiary of Roche’s discontinuation of an investigational spinal muscular atrophy drug is Scholar Rock, which was hobbled by manufacturing concerns at a Novo Nordisk...
-
Uncategorized3 weeks agoLilly wins appeal for donanemab, drug to be reconsidered for NHS
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for...
-
Uncategorized3 weeks agoFDA finds lack of evidence for dry eye disease drug approval
Aldeyra Therapeutics has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) of reproxalap, an...
-
Uncategorized3 weeks agoTGA approves trial for first-in-human multiple myeloma therapy
Australia’s Therapeutic Goods Administration (TGA) has approved a first-in-human trial of a T-cell therapy in multiple myeloma. The therapy, developed by HaemaLogiX in collaboration with the Peter MacCallum...
-
Uncategorized3 weeks ago
Novo’s High Dose Wegovy Scores FDA Priority Voucher Program’s 4th Nod
With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program,...
-
Uncategorized3 weeks agoMestag raises $40m to advance therapeutic cancer treatment
Mestag Therapeutics has raised $40 million financing to advance its new therapeutic cancer treatment. The closing of the financing round, led by life science investors SV Health Investors...
-
Uncategorized3 weeks ago
AstraZeneca Building Shanghai Production Plant to Support Cell Therapy Strategy
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.
-
Uncategorized3 weeks ago
Sarepta Plans FDA Run for Duchenne Exon Skippers Despite Confirmatory Trial Failure
Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether...
Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI
Microplastics in Human Bile Drive Mitochondrial Dysfunction and Senescence
